Drug de-escalation is primarily driven by the need to spare patients unnecessary toxicity and the associated side effects and repeated hospital visits. However, de-escalation strategies may also have the potential to reduce treatment costs.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Multiple sclerosis
Unexpected side effects when switching from natalizumab to a biosimilar
- Immunotherapy
Subcutaneously or intravenously?
- Work-related asthma
When the job leads to exacerbations
- Inoperable NSCLC
Efficacy of pembrolizumab in combination with concurrent chemoradiotherapy
- De-escalation strategies
De-escalation strategies – less is more
- Pain and autism
Hurdles to pain treatment for autistic patients
- Advanced NSCLC
MARIPOSA: Combination therapy as the new standard of care for EGFR-mutated NSCLC
- Pathophysiological mechanisms and therapeutic perspectives